Caterpillar bids for Australia’s RPMGlobal- AFR
Entero Therapeutics, Inc. (NASDAQ:ENTO) announced Monday that it has received an extension from the Nasdaq Stock Market to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. The extension, granted following the company’s timely submission of a compliance plan, gives Entero Therapeutics until October 8, 2025, to meet the requirements outlined in Nasdaq Listing Rule 5550(b)(1).
According to a statement based on a recent SEC filing, the company must comply with certain terms of the extension to maintain its listing. If Entero Therapeutics does not regain and demonstrate compliance with the rule by the deadline, it may face delisting. In that event, Nasdaq’s rules allow the company to appeal any delisting determination to a Nasdaq Hearing Panel. The company noted that there is no assurance it will be able to regain compliance or maintain its listing.
Previously, on April 11, 2025, Entero Therapeutics received a notice from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement. The company’s stockholders’ equity was reported as negative $3,876,738 in its annual report for the period ended December 31, 2024, below the required minimum of $2.5 million. Entero Therapeutics also did not meet alternative compliance standards related to market value of listed securities or net income from continuing operations.
The company’s common stock continues to trade on the Nasdaq Capital Market under the symbol ENTO.
All information is based on a press release statement and the company’s SEC filing.
In other recent news, Entero Therapeutics, Inc. has been notified by Nasdaq about non-compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. The company’s equity was reported as negative $3.87 million as of December 31, 2024, falling short of the required $2.5 million. Entero Therapeutics also failed to meet alternative compliance standards related to market value or net income. The company has until May 26, 2025, to submit a compliance plan to Nasdaq. If accepted, Entero could have until October 8, 2025, to meet the listing requirements. Entero Therapeutics intends to submit a plan within the specified timeframe, although there is no assurance of acceptance by Nasdaq. The company retains the right to appeal should their plan be rejected. This development was reported following a formal letter from Nasdaq received on April 11, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.